Cargando…
Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women
OBJECTIVES: To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days [Treatment 1]) compared with two traditional 21/7 regimens (21 days 150 μg LNG/30 μg EE [Treatment 2]...
Autores principales: | Nappi, Rossella E., Paoletti, Anna Maria, Volpe, Annibale, Chiovato, Luca, Howard, Brandon, Weiss, Herman, Ricciotti, Nancy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134112/ https://www.ncbi.nlm.nih.gov/pubmed/24923685 http://dx.doi.org/10.3109/13625187.2014.918596 |
Ejemplares similares
-
Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians
por: Nappi, Rossella E., et al.
Publicado: (2016) -
Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women
por: Kim, Nayoung, et al.
Publicado: (2015) -
Breast cancer and combined oral contraceptives: results from a multinational study. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
Publicado: (1990) -
Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature
por: Nappi, Rossella E, et al.
Publicado: (2014) -
Breast cancer and combined oral contraceptives.
por: Shelton, J. D.
Publicado: (1990)